The Ethos-PUSH study seeks to deliver a highly advanced program investigating the use of novel drugs for the treatment of hemangiosarcoma (HSA) with the goal of curing this aggressive cancer. Ethos Discovery’s previous work in HSA has taught us that HSA is not a single cancer but is rather at least four different subtypes of cancer, each characterized by a different genomic mutation. Previous studies evaluating drugs for the treatment of HSA have shown variable results, and the discovery of these different subtypes could explain this phenomenon.
This study will ask if drugs specifically matched to these genomic subtypes of patients with HSA can improve their outcomes. Our trial has already demonstrated that a greater number of dogs (40-50%) with a ruptured splenic tumor end up having a benign diagnosis that is cured with surgery alone.
- Any dog diagnosed with a ruptured splenic tumor whose owners are pursuing surgery for splenectomy.
- No evidence of metastasis as determined via chest x-rays and during surgery.
- Dogs weighing more than 5kg and less than 45kg
What We’ve Learned:
- We have learned that many splenic tumors are benign (40-50%) and can be cured with surgery alone.
- Enrolling participants in this trial offers owners and their pets more hope.
- Future dogs and humans will benefit from the results of this research.
What to Expect
Eligible patients will have various blood, tissue, and fecal samples collected at the time of splenectomy surgery. Patients found to have HSA following surgery will be eligible to continue on to the second phase of the trial and will receive cutting-edge therapies at no cost to the pet owner.
- Procedures typically begin 1 week after the splenectomy surgery.
- This study consists of around 10 study visits over 1 year.
Pet Owner Resources
Click the links below for more information about eligibility, steps, timelines, and treatments associated with this study.
Enroll or request more information below